Keytruda 100 MG/4 ML vial 4ML
Ended Awarded
- Contract number
- SPE2DB26FX1JP
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $115,914
Award facts
- Contract value 100% obligated
- $115,913.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Keytruda 100 mg/4 ml vials. The contract, valued at $115,913.80 on a firm fixed-price basis, is scheduled for completion by October 30, 2025, and was awarded on October 8, 2025. This delivery order carries no set-aside designation, allowing the vendor to compete on a competitive basis despite its small business status. The place of performance is Park Ridge, Illinois, where DMS Pharmaceutical Group maintains its operations.
This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency valued at $499,999,999 and extending through November 2026. The parent IDC, established under the DLA's SPE2DB pharmaceutical supply program, enables the agency to procure a comprehensive portfolio of prescription medications, biologics, and medical consumables to support Department of Defense healthcare facilities worldwide. As a critical supplier within the federal pharmaceutical supply chain, DMS Pharmaceutical Group has consistently delivered specialized pharmaceuticals including oncology treatments, immunizations, and other prescription products to military medical installations. The Keytruda delivery under this order supports DoD healthcare requirements for cancer treatment medications.
Quick answers
Who was awarded contract SPE2DB26FX1JP?
SPE2DB26FX1JP was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 8, 2025.
How much is contract SPE2DB26FX1JP worth?
The government has obligated $115,914 on SPE2DB26FX1JP.
Is contract SPE2DB26FX1JP an order under another contract?
Yes. SPE2DB26FX1JP is a delivery order under SPE2DB22D9353, an indefinite delivery contract.
Was contract SPE2DB26FX1JP competed?
The extent of competition for SPE2DB26FX1JP was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award